Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 4/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7108959 | 1.00 | EPHX1 (0.38) | EPHX1LMNACYP2C19HIF1AMAPT | |
| SCHEMBL19355183 | 0.81 | GAA (0.43) | LMNAMAPTALDH1A1KDM4ERAB9A | |
| SCHEMBL19656683 | 0.81 | TSHR (0.34) | LMNACYP2C19HIF1AMAPTALDH1A1 | |
| SCHEMBL27252550 | 0.80 | MAPT (0.38) | EPHX1MAPTALDH1A1RAB9ATSHR | |
| SCHEMBL13592491 | 0.80 | MTNR1A (0.40) | EPHX1HIF1AMAPTALDH1A1KDM4E | |
| SCHEMBL13037022 | 0.80 | GABRR1 (0.38) | EPHX1LMNAMAPTALDH1A1RAB9A | |
| SCHEMBL17794013 | 0.80 | ALDH1A1 (0.35) | LMNACYP2C19HIF1AALDH1A1EGFR | |
| SCHEMBL1222348 | 0.79 | TDP1 (0.49) | EPHX1LMNAKDM4EMEN1KMT2A | |
| SCHEMBL1222350 | 0.79 | TDP1 (0.49) | EPHX1LMNAKDM4EMEN1KMT2A | |
| SCHEMBL3166361 | 0.79 | TDP1 (0.49) | EPHX1LMNAKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104629573-B | The manufacture method of optical component and the application of the ultraviolet-curing resin composition for this manufacture method | 日本化药株式会社 | 2016-09-14 | — | — | CN | claimed |
| US-20170342046-A1 | Fatty Acid Cysteine-Based Conjugates and Their Use in Treating Medical Disorders | CATABASIS PHARMACEUTICALS, INC. | 2017-11-30 | — | — | US | disclosed |
| CN-104629573-B | The manufacture method of optical component and the application of the ultraviolet-curing resin composition for this manufacture method | 日本化药株式会社 | 2016-09-14 | — | — | CN | disclosed |
| EP-1071654-B1 | A PROCESS FOR PREPARING CHIRAL (S)-2,3-DISUBSTITUTED-1-PROPYLAMINE DERIVATIVES | SAMSUNG FINE CHEMICALS CO LTD (KR) | 2003-10-22 | — | — | EP | disclosed |
| US-6417403-B1 | AMINATION OF 3,4-DISUBSTITUTED-1-BUTANECARBONYL DERIVATIVE THROUGH CURTIUS OR HOFMAN REARRANGEMENT; SALT FORMATION, CARBAMYLATION | SAMSUNG FINE CHEMICALS CO., LTD. (KR) | 2002-07-09 | — | — | US | disclosed |
| CN-1301248-A | Process for preparing chiral (S)-2, 3-disubstituted-1-propylamine derivatives | SAMSUNG FINE CHEMICALS CO LTD (KR) | 2001-06-27 | — | — | CN | disclosed |
| EP-1071654-A1 | A PROCESS FOR PREPARING CHIRAL (S)-2,3-DISUBSTITUTED-1-PROPYLAMINE DERIVATIVES | Samsung Fine Chemicals Co., Ltd. (KR) | 2001-01-31 | — | — | EP | disclosed |
| WO-1999052855-A1 | A PROCESS FOR PREPARING CHIRAL (S)-2,3-DISUBSTITUTED-1-PROPYLAMINE DERIVATIVES | SAMSUNG FINE CHEMICALS CO., LTD. (KR) | 1999-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342046-A1 | Fatty Acid Cysteine-Based Conjugates and Their Use in Treating Medical Disorders | CPT2, FABP1, ACAA2 | EPHX1 1525/4885LMNA 3607/4885CYP2C19 3277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.